News Breaks |
|
|
| March 12, 2013 |
| 14:25 EDT |  | AMGN, AMGN, LLY, LLY, MDCO, MDCO, REGN, REGN, SNY, SNY, AZN, AZN, MRK, MRK | Leerink's biotech analysts hold an analyst/industry conference call
Following the recently held American College of Cardiology Conference, Biotech Analysts Fernandez and Schwartz discuss reactions to MRK/Oxford's final HPS2 THRIVE data, impact of potential IMPROVE-IT outcomes on Vytorin/Zetia & novel lipid-lowering drugs, potential impact of Cangrelor introduction on AZN’s Brilinta and LLY/Daiichi Sankyo’s Effient on an Analyst/Industry conference call to be held on March 12 at 3 pm. |
|
|
News For AMGN;LLY;MDCO;REGN;SNY;AZN;MRK From The Last 14 Days Check below for free stories on AMGN;LLY;MDCO;REGN;SNY;AZN;MRK the last two weeks. |
|
|
| May 23, 2013 |
| 17:04 EDT |  | MRK | Merck's preladenant gave no evidence of efficacy, ends regulatory filing pursuit
 Subscribe for More Information |
|
| 08:18 EDT | | SNY | Merrimack completes enrollement in a Phase 2 study of MM-121 with Sanofi
Subscribe for More Information |
|
| 07:48 EDT |  | MDCO | The Medicines Co. decline unjustified, says RBC Capital
Subscribe for More Information |
|
| May 22, 2013 |
| 18:52 EDT | | MRK | On The Fly: After Hours Movers
UP AFTER EARNINGS: Hewlett-Packard (HPQ), up 13.4% after reporting second quarter earnings that beat expectations and guiding third quarter and full-year earnings above estimates... Pacific Sunwear (PSUN), up 14.3%. ALSO HIGHER: Merck (MRK), up 0.2% after an FDA advisory panel voted 13-3 in support of the safety of initial doses of its insomnia drug suvorexant. DOWN AFTER EARNINGS: DryShips (DRYS), down 4.7%. ALSO LOWER: Apricus Biosciences (APRI), down 11.5% after filing to sell an ungiven amount of stock... NCI Building Systems (NCS) after being replaced by Cynosure (CYNO) in the S&P 600 as of May 31. |
|
| 18:32 EDT | | MRK | Merck's suvorexant for insomnia reviewed by FDA advisory committee
Subscribe for More Information |
|
| 18:06 EDT |  | MRK | Merck insomnia drug gets FDA panel backing, WSJ reports
Merck's insomnia drug suvorexant received a favorable 13-3 vote from an FDA panel on the drug's two proposed starting doses, with the panel splitting the vote on the safety of higher doses, reports the Wall Street Journal. Reference Link |
|
| 16:16 EDT | | MRK | FDA panel votes 13-3 that Merck insomnia drug safe in low doses, Bloomberg says
Subscribe for More Information |
|
| 16:00 EDT |  | MRK | Options Update; May 22, 2013
Subscribe for More Information |
|
| 15:16 EDT | | MDCO | The Medicines Co. shares defended at ISI Group
Subscribe for More Information |
|
| 14:52 EDT | | MRK | FDA panel says Merck insomnia drug effective as sleep aid, Bloomberg reports
Subscribe for More Information |
| |
| 12:25 EDT | | REGN | Stocks with call strike movement; GME REGN
Subscribe for More Information |
|
| 09:39 EDT | | MRK | Active equity option families trading
Subscribe for More Information |
|
| 09:01 EDT | | AZN | Par Pharmaceutical begins shipment of generic Atacand
Subscribe for More Information |
|
| 07:45 EDT | | MRK | FDA Peripheral & Central Nervous System Drugs Advisory Committee holds a meeting
Subscribe for More Information |
|
| May 21, 2013 |
| 18:56 EDT | | MRK | On The Fly: After Hours Movers
Subscribe for More Information |
|
| 17:03 EDT | | MRK | Merck announces $5B share repurchase
Subscribe for More Information |
|
| 17:01 EDT | | MRK | Merck announces $5B accelerated share repurchase
Subscribe for More Information |
|
| 12:13 EDT | | MDCO | The Medicines Co. weakness a buying opportunity, says Credit Suisse
Subscribe for More Information |
|
| 11:49 EDT | | MDCO | The Medicines Co. weakness not related to fundamentals, says ISI Group
ISI Group said they spoke with The Medicines Company management and haven't found anything fundamental to explain today's weakness. The analyst also confirmed there was nothing new regarding the ongoing Angiomax litigation with the Judge's office and said today's AcelRx Ph. 3 data provided no new information. |
|
| 10:24 EDT |  | MDCO | The Medicines Co. spike lower, levels to watch
Subscribe for More Information |
| |
|
|
|
|
